Revoking the privilege: Targeting HER2 in the central nervous system

Molecular Pharmacology

Volumn 73, Issue 2, 2008, Pages 271-273

  Contessa, Joseph N ^a   Hamstra, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; JNJ 2871063; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL TYPE; CENTRAL NERVOUS SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PENETRATION; GENE FUNCTION; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEMS; GENE TARGETING; HUMANS; RECEPTOR, ERBB-2;

EID: 38549179541     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.042986     Document Type: Short Survey

References (20)

1. Bria E, Cuppone F, Fornier M, Nistico C, Carlini P, Milella M, Sperduti I, Terzoli E, Cognetti F, and Giannarelli D (2008) Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat, in press.
2. Chakravarti A, Berkey B, Robins HI, Guha A, Curran W, Brachman D, Shultz M, and Mehta M (2006) An update of phase II results from RTOG 0211: a phase I/II study of gefitinib+radiation of newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys 66:S83-S84.
3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, and Talpaz M (2001a) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al. (2001b) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037.
5. Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butter J, Borowski V, et al. (2008) Cellular and in vivo activity of JNJ-28871063, a nenquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 73:328-348.
6. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, and Lenihan DJ (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820-7826.
7. Gilbertson RJ, Jaros EB, Perry RH, and Pearson AD (1992) Prognostic factors in medulloblastoma. Lancet 340:480.
8. Gilbertson RJ, Pearson AD, Perry RH, Jaros E, and Kelly PJ (1995) Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 71:473-477.
9. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Nat Cancer Inst 97:880-887.
10. Herms JW, Behnke J, Bergmann M, Christen HJ, Kolb R, Wilkening M, Markakis E, Hanefeld F, and Kretzschmar HA (1997) Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 19:510-515.
11. Hernan R, Fasheh R, Calabrese C, Frank AJ, Maclean KH, Allard D, Barraclough R, and Gilbertson RJ (2003) ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63:140-148.
12. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158.
13. Krishnan S, Brown PD, Ballman KV, Fiveash JB, Uhm JH, Giannini C, Jaeckle KA, Geoffroy FJ, Nabors LB, and Buckner JC (2006) Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 65:1192-1199.
14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672.
16. Polkinghorn WR and Tarbell NJ (2007) Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4:295-304.
17. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, et al. (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142.
18. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684.
19. Sordella R, Bell DW, Haber DA, and Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305:1163-1167.
20. Tong CY, Hui AB, Yin XL, Pang JC, Zhu XL, Poon WS, and Ng HK (2004) Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg 100 (2 Suppl):187-193.